Last updated: April 3, 2026
India’s patent system for biopharmaceuticals encompasses specific challenges and opportunities. Recent reforms and jurisprudence influence patentability criteria, scope of claims, and enforcement strategies.
What Are the Patentability Criteria for Biopharmaceuticals in India?
India requires that biopharmaceutical inventions satisfy the standard criteria outlined in the Patent Act, 1970, particularly Sections 3 and 5-5A, which list exclusions and scope limitations specific to biotech and pharmaceutical inventions.
Patent-Eligible Innovations
- Novelty: The invention must be new; prior disclosures—published data, prior patents, or public research—can invalidate the patent claim. For biopharmaceuticals, filings post-2019 increasingly emphasize demonstrating unexpected technical advantage or unpredictable clinical effects.
- Inventive Step: The invention must not be obvious to a person skilled in the art. Courts assess whether the inventive step involves technical advancement beyond existing knowledge standard in the biopharma field.
- Utility: The invention must have specific, substantial, and credible utility. For biopharmaceuticals, this includes therapeutic efficacy, pharmacological activity, or manufacturing utility.
Double Patentability Restrictions and Patentable Subject Matter
India restricts patents on certain biotechnology and pharmaceutical inventions under Section 3:
- Section 3(d): The patenting of incremental modifications of known drugs is limited unless they demonstrate enhanced efficacy. For instance, the patenting of second-generation formulations requires evidence of increased therapeutic benefit.
- Section 3(i): Natural substances, including genes, proteins, or microorganisms, are excluded unless modified substantially through inventive steps.
- Section 3(c): Laws of nature, natural phenomena, and abstract ideas are not patentable.
Latest case law (e.g., Novartis v. Union of India, 2013) reinforced that mere discovery of a known substance, without demonstrating enhanced efficacy, cannot be patented.
What Affects the Enforceability of Biopharmaceutical Patents?
India’s patent enforcement landscape involves several key considerations:
- Patent Office Validity Challenges: Post-grant oppositions are common. The Indian Patent Appellate Board (IPAB) and courts can revoke patents based on lack of novelty, inventive step, or inadequate disclosure.
- Compulsory Licensing: Based on public health needs, the government can grant licenses for patented biopharmaceuticals if deemed necessary, complicating enforceability.
- Patent Working Requirements: Section 146 mandates that patents be worked within India, with non-working potentially leading to compulsory licensing or revocation.
- Infringement Litigation: Enforcement involves civil suits. Patents covering methods of manufacturing or specific formulations are enforceable if claims are accurately drafted and enforceable against infringing parties.
How Broad Can the Claims Be for Biopharmaceutical Patents?
Scope depends on claim drafting strategies, judicial interpretation, and existing prior art.
Types of Claims
- Product Claims: Cover novel compounds, biologics, or formulations. These require demonstrating genuine novelty and inventive step, especially under Section 3(d) constraints.
- Process Claims: Protect manufacturing methods, often considered broader but require detailed description to meet Section 10 disclosure standards.
- Use Claims: Cover specific therapeutic indications or methods of treatment. These are easier to defend if supported by experimental data.
- Composition of Matter Claims: Typically offer the broadest scope but are vulnerable under Section 3(d) if incremental modifications are claimed without increased efficacy.
Claim Drafting Strategies
- Focus on structural features and specific uses rather than broad function-based language.
- Include detailed process steps for manufacturing to strengthen scope.
- Use multiple dependent claims to cover alternative embodiments without overextending.
Judicial Trends and International Comparison
India’s courts have adopted a pragmatic approach, balancing innovation promotion with public health concerns. The doctrine of “inventive step” tends to be strict; broad claims are often narrowed during prosecution or litigation.
Compared to global standards (e.g., US, Europe), India’s claims are more conservative, especially for biopharmaceuticals, emphasizing efficacy and detailed disclosures.
Summary of Key Policy and Legal Developments
| Aspect |
Recent Developments |
Impact |
| Patentability (Section 3) |
Stricter scrutiny post-Novartis ruling |
Increased focus on demonstrating efficacy and inventive step |
| Patent Scope |
Courts favor narrow, specific claims |
Broader claims are challenged or limited during prosecution |
| Enforcement |
Increased pre- and post-grant opposition |
Patents vulnerable to revocation if not carefully drafted |
| Compulsory Licensing |
Utilized for public health, especially COVID-19 |
Limits enforceability in certain fields |
Key Takeaways
- Patentability is narrowly interpreted for biopharmaceuticals under Sections 3 and 5–5A; demonstrating efficacy is crucial.
- Patent enforceability depends on robust prosecution, enforcement strategies, and awareness of post-grant challenges.
- Claim scope should align with the inventive contribution, emphasizing specificity and supported data.
- Recent case law reinforces the importance of comprehensive disclosures and genuine innovation.
- Patent strategies must balance broad protection with legal constraints, especially in highly regulated sectors.
FAQs
1. Can naturally occurring genes be patented in India?
Only if the gene is modified substantially through inventive steps, as natural genes are excluded under Section 3(i).
2. How does Section 3(d) impact patenting second-generation drugs?
It restricts patents unless the new form demonstrates enhanced therapeutic efficacy over prior forms.
3. What are common grounds for patent revocation in India?
Lack of novelty, obviousness, non-utility, or failure to meet disclosure requirements.
4. Are method-of-treatment patents enforceable in India?
Yes, if adequately claimed and supported, but courts scrutinize such claims for clarity and inventive step.
5. What are best practices for drafting scope of claims?
Draft specific, structurally based claims supported by detailed experimental data; avoid overly broad language that lacks novelty or inventive step.
References
[1] Novartis AG v. Union of India, (2013) 6 SCC 1.
